FDA seeks public input on whether cannabis, CBD should be descheduled

As the cannabis plant awaits a high-stakes review from international health authorities, the U.S. Food and Drug Administration (FDA) is asking the public to weigh in on whether cannabis, CBD and other cannabis extracts should be declassified as a controlled substance.

The United Nations' World Health Organization (WHO) made a preliminary announcement in December that CBD has a low potential for abuse and shouldn't be scheduled as a controlled substance.

FDA seeks public input on whether cannabis, CBD should be descheduled is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs